Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | FiercePharma
Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace
Another setback for Teva's laquinimod in MS - PMLiVE
![Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)](https://mma.prnewswire.com/media/1019389/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of_a_Bioequ.jpg "Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)")
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Proneuron to sue Teva for billions in Copaxone damages - Globes
Generic drugs giant Teva to cut workforce by more than 25%
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
New MS Drug Ocrevus Wins FDA Approval
18. Teva Pharmaceutical Industries | FiercePharma
Court refuses injunctions in pharma patent case
FDA approves first MS drug for aggressive multiple sclerosis: ocrelizumab (Ocrevus) - CBS News
Teva knocked as competition fears grow for MS drug | Financial Times
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion | FiercePharma
FDA approves first generic version of epilepsy drug Sabril from Teva
Teva Pays $925,000 to Settle Mississippi Drug-Price Case, Seek More Pacts - Bloomberg
Teva Pharmaceuticals - Wikipedia
Teva Found Liable for Fueling Opioid Addiction in New York - WSJ
Teva embroiled in Copaxone dosage levels dispute - Globes
Teva Pharmaceutical Facing EU Antitrust Investigation Over Patent Strategy for MS Drug - IP News Shots
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Pioglitazone Could Play a Role in MS Treatment | Everyday Health
New MS Drug Ocrevus Wins FDA Approval
Teva must face government's kickback claims over Copaxone - judge | Reuters
